title: Prostate-Specific Antigen Density and Gleason Score Predict Adverse Pathologic Features in Patients with Clinically Localized Prostate Cancer.
abstract: BACKGROUND
  According to recent studies, prostate cancer is the second most common cancer among Iranian men. Radical prostatectomy has been considered the gold standard treatment in patients with clinically localized prostate cancer. Gleason score, PSA density, and PSA velocity are some of the parameters used to predict adverse pathologic features.
  
  
  OBJECTIVE
  The aim of this study was to evaluate the prognostic value of PSA density and Gleason score in predicting adverse pathologic features in patients with localized prostate cancer who undergo radical prostatectomy.
  
  
  METHODS
  We conducted a cross-sectional study of 105 patients with localized prostate cancer who underwent radical prostatectomy between 2006 and 2013. We recorded Gleason scores and PSA levels, in addition to the results of pathological evaluations after radical prostatectomy, including prostate volume, stage, LNI (lymph node involvement), SVI (seminal vesicle invasion), and extraprostatic extension (EPE). Data were analyzed using SPSS version 21.
  
  
  RESULTS
  Mean PSA density was 0.27 (0.17 SD). The frequencies of EPE, SVI, and LNI were 21.9, 16.2, and 2.9, respectively. The Mann-Whitney U-test demonstrated a significant correlation between PSA density and adverse pathologic features (EPE, SVI, and LNI).
  
  
  CONCLUSIONS
  PSA, PSA density, and Gleason score should be considered together in order to more accurately predict the adverse pathologic features of prostate cancer.
authors.affiliation: Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, IR Iran.
authors.forename: Mohammad Reza
authors.initials: MR
authors.lastname: Nowroozi
authors.affiliation: Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, IR Iran.
authors.forename: Seyed Ali
authors.initials: SA
authors.lastname: Momeni
authors.affiliation: Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, IR Iran.
authors.forename: Solmaz
authors.initials: S
authors.lastname: Ohadian Moghadam
authors.affiliation: Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, IR Iran.
authors.forename: Elnaz
authors.initials: E
authors.lastname: Ayati
authors.affiliation: Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, IR Iran.
authors.forename: Afshin
authors.initials: A
authors.lastname: Mortazavi
authors.affiliation: Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, IR Iran.
authors.forename: Simin
authors.initials: S
authors.lastname: Arfae
authors.affiliation: Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, IR Iran.
authors.forename: Hassan
authors.initials: H
authors.lastname: Jamshidian
authors.affiliation: Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, IR Iran.
authors.forename: Mohsen
authors.initials: M
authors.lastname: Taherimahmoudi
authors.affiliation: Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, IR Iran.
authors.forename: Mohsen
authors.initials: M
authors.lastname: Ayati
keywords: Adverse Pathologic Feature; PSA Density; Prostate Neoplasm